文献速递妇科

分子定义子宫内膜癌队列中的HER2表达:SPECTRUM研究

HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
PubMed 文献 · Gynecol Oncol · 2025-02-12

该回顾性分析纳入193例子宫内膜癌患者,按ASCO/CAP子宫内膜、胃和乳腺标准评估HER2表达。按子宫内膜标准,HER2阴性占69.9%、HER2低表达占25.8%、HER2阳性占4.3%,HER2低表达在POLEmut(66.7%)和p53abn(45.1%)亚型中最常见。HER2状态对无复发生存和总生存均无影响,仅诊断分期与生存相关。

要点

  • 按子宫内膜标准,HER2低表达占25.8%,以POLEmut和p53abn亚型最常见。
  • 子宫内膜与胃标准HER2判读一致性达88.7%,子宫内膜标准检出更多HER2低表达。
  • HER2低表达或阳性与阴性相比,对无复发生存和总生存均无影响。

核心结论

  • 本研究揭示了HER2低表达在子宫内膜癌分子亚型中的分布,子宫内膜标准对识别HER2低表达更敏感,但HER2状态在该队列中无预后价值。

研究设计与样本

  • 回顾性分析纳入193例子宫内膜癌患者,包括111例低级别子宫内膜样癌和82例高级别子宫内膜癌(含多种组织学类型),按组织学和分子分型分类,采用ASCO/CAP子宫内膜、胃和乳腺HER2评分指南评估。

主要发现

  • 按子宫内膜标准,HER2阴性占69.9%,HER2低表达占25.8%,HER2阳性占4.3%。
  • HER2低表达在POLEmut亚型中占66.7%,在p53abn亚型中占45.1%。
  • 不同肿瘤区域之间及原发肿瘤与复发肿瘤之间HER2表达异质性低。
  • 子宫内膜与胃标准的一致性为88.7%,子宫内膜指南检出更多HER2低表达病例。
  • HER2低表达或HER2阳性 versus HER2阴性对无复发生存或总生存均无影响,诊断分期是唯一与生存相关的因素,年龄仅与总生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2 antibody-drug conjugates like Trastuzumab deruxtecan (TDxd) have shown efficacy in HER2-low cancers, however the prevalence and clinical impact of HER2-low in endometrial cancer (EC) remains unclear. This study investigates HER2 expression in EC, focusing on HER2-low frequency, its distribution across histologic and molecular subtypes, intratumoral heterogeneity, and prognostic significance. METHODS: This retrospective analysis included EC patients categorized histologically and molecularly, using ASCO/CAP HER2 scoring guidelines for endometrial, gastric, and breast cancers. The main aim was to determine HER2-low frequency by molecular subtype, with secondary goals of assessing HER2 heterogeneity, changes between primary and recurrent tumors, guidelines concordance and the impact of HER2 status on recurrence-free (RFS) and overall survival (OS). RESULTS: 193 EC patients were included, 111 low grade endometrioid EC and 82 high grade EC with various histotypes. Based on endometrial criteria, 69.9 % were HER2-negative, 25.8 % HER2-low, and 4.3 % HER2-positive, with HER2-low being most common in POLEmut (66.7 %) and p53abn (45.1 %) subtypes. Low heterogeneity in HER2 expression was observed between different tumors areas and between primary tumors and their recurrences. The endometrial and gastric criteria had high concordance (88.7 %), with endometrial guidelines detecting more HER2-low cases. Neither HER2-low nor HER2-positivity versus HER2-negativity had an impact on RFS or OS, with the stage at diagnosis being the only factor associated with survival, while age was associated only with OS. CONCLUSIONS: This study highlights the distribution of HER2-low across EC molecular subtypes, with endometrial criteria proving more sensitive for identifying HER2-low cases, though HER2 status had no prognostic value in this cohort.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cortés-Salgado A, Moreno-Moreno E, Carretero-Barrio I, et al. HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study. Gynecol Oncol. 2025. PMID: 39947031. doi:10.1016/j.ygyno.2025.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。